Top

Published in:

Open Access 01-04-2020 | Prostate Cancer | Original Article

Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study

Authors: Kliton Jorgo, Csaba Polgar, Tibor Major, Gabor Stelczer, Andras Herein, Tamas Pocza, Laszlo Gesztesi, Peter Agoston

Published in: Pathology & Oncology Research | Issue 2/2020

Asbtract

To evaluate the acute and late toxicity using moderately hypofractionated, intensity-modulated radiotherapy (IMRT) with a simultaneous integrated boost (SIB) to prostate for patients with intermediate and high risk prostate cancer. From 2015 to 2017, 162 patients were treated with IMRT with SIB to the prostate. IMRT plans were designed to deliver 50.4Gy in 28 fractions (1.8 Gy/fraction) to the pelvic lymph nodes (whole pelvis radiotherapy, WPRT) while simultaneously delivering 57.4 Gy in 28 fractions (2.05 Gy/fraction) to the seminal vesicles and 70 Gy in 28 fractions (2.5 Gy/fraction) to the prostate for high risk patients. For intermediate risk patients the same technique was applied, without WPRT. Acute and cumulative late genitourinary (GU) and gastrointestinal (GI) toxicities were scored according to the Radiation Therapy Oncology Group (RTOG) scoring system. Of the 162 patients enrolled, 156 (96%) completed the treatment as planned. The median follow-up time was 30 months. Seventy-eight patients (48.2%) were treated with WPRT. The rate of acute grade ≥ 2 GI and GU toxicities in all patients were 22% and 58%, respectively. The rate of cumulative late grade ≥ 2 GI and GU toxicities were 11% and 17%, respectively. Acute grade 3 GI and GU toxicities occurred in 1% and 1%. Late grade 3 GI and GU side effects occurred in 5% and 4%, respectively. None of the patients developed grade ≥ 4 toxicity. IMRT with SIB technique using moderate hypofractionation to the prostate is feasible treatment option for intermediate and high risk patients, associated with low rate of severe GU and GI toxicities.

Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the M.D. Anderson randomized dose-escalation trial for prostatecancer. Int J Radiat Oncol Biol Phys 70:67–74PubMed

Peeters ST, Heemsbergen WD, Koper PC et al (2006) Dose-responsein radiotherapy for localized prostate cancer: results of theDutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990–1996PubMed

Zietman AL, DeSilvio ML, Slater JD et al (2005) Comparison of conventional-dose vs. high-dose conformal radiation therapyin clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294:1233–1239PubMed

Miralbell R, Roberts SA, Zubizarreta E et al (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 82:1017–1024

Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43:1095–1101PubMed

Tree AC, Khoo VS, van As NJ et al (2014) Is biochemical relapse-free survival after profoundly hypofractionated radiotherapy consistent with current radiobiological models? Clin Oncol 26:216–229

Lee WR, Koontz BF (2018) Moderate hypofractionation for prostate cancer. Transl Androl Urol 7:321–329PubMedPubMedCentral

Roach M III (1993) Re: the use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:1923–1924PubMed

Joniau S, Van den Bergh L, Lerut E et al (2013) Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol 63:450–458PubMed

10.

Heidenreich A, Varga Z, Von Knobloch R (2002) Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 167:1681–1686PubMed

11.

Bader P, Burkhard FC, Markwalder R et al (2002) Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 168:514–518PubMed

12.

Wyler SF, Sulser T, Seifert HH, Ruszat R, Forster TH, Gasser TC, Bachmann A (2006) Laparoscopic extended pelvic lymph node dissection for high-risk prostate cancer. Urology 68:883–887PubMed

13.

Arenas LF, Füllhase C, Boemans P et al (2010) Detecting lymph nodes metastasis in prostate cancer through extended vs. standard laparoscopic pelvic lymphadenectomy. Aktuelle Urol 41:S10–S14PubMed

14.

Seaward SA, Weinberg V, Lewis P, Leigh B, Phillips TL, Roach M III (1998) Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 42:1055–1062PubMed

15.

Seaward SA, Weinberg V, Lewis P et al (1998) Identification of a high-risk clinically localised prostate cancer subgroup receiving maximum benefit from whole pelvic irradiation. Cancer J Sci Am 4:370–377PubMed

16.

Pan CC, Kim KY, Taylor JM et al (2002) Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 53:1139–1145PubMed

17.

Aizer AA, Yu JB, McKeon AM et al (2009) Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 75:1344–1349PubMed

18.

Milecki P, Baczyk M, Skowronek J et al (2009) Benefit of whole pelvis radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer. J Biomed Biotechnol 2009:625394PubMedPubMedCentral

19.

Mantini G, Tagliaferri L, Mattiucci GC et al (2011) Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys 81:721–726

20.

Asbell SO, Martz KL, Shin KH et al (1998) Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOP 77-06, a phase III study for T1bN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 40:769–782PubMed

21.

Lawton CA, DeSilvio M, Roach M et al (2007) An update of the phase III trial comparing whole-pelvic to prostate-only radiotherapy and neo-adjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69:646–655PubMedPubMedCentral

22.

Pommier P, Chabaud S, Lagrange JL et al (2007) Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25:5366–5373PubMed

23.

D’Amico AV, Moul J, Carroll PR et al (2003) Cancer-specific mortality after surgery orradiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 21:2163–2172PubMed

24.

Kószó, R., Varga, L., Fodor, E., Kahán Z., Cserháti A., Hideghéty K., Együd Z., Szabó C., Borzási E., Szabó D., Müllner K., Varga Z., Maráz A. (2018) Prone positioning on a belly board decreases rectal and bowel doses in pelvic intensity-modulated radiation therapy (IMRT) for prostate. Cancer Pathol Oncol Res https://doi.org/10.1007/s12253-018-0436-2

25.

Lawton CA, Michalski J, El-Naqa I et al (2009) RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 74:383–387PubMed

26.

Chao KK, Goldstein NS, Yan D, Vargas CE, Ghilezan MI, Korman HJ, Kernen KM, Hollander JB, Gonzalez JA, Martinez AA, Vicini FA, Kestin LL (2006) Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension? Int J Radiat Oncol Biol Phys 65:999–1007PubMed

27.

Arcangeli G, Saracino B, Arcangeli S et al (2017) Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial. J Clin Onco l35:1891–1897

28.

Pollack A, Walker G, Horwitz EM, Price R, Feigenberg S, Konski AA, Stoyanova R, Movsas B, Greenberg RE, Uzzo RG, Ma C, Buyyounouski MK (2013) Randomized trial of hypofractionated external beam radiotherapy for prostate cancer. J Clin Oncol 31:3860–3868PubMedPubMedCentral

29.

Hoffman KE, Voong KR, Levy LB, Pugh TJ, Choi S, du W, Frank SJ, Johnson JL, Kudchadker R, Nguyen QN, Lee A, Mahmood U, McGuire SE, Kuban DA (2016) Randomized trial of hypofractionated dose-escalated intensity modulated radiation therapy versus conventionally fractionated intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 96:S32

30.

Incrocci L, Wortel RC, Alemayehu WG et al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with localized prostate cancer (HYPRO): final efficacy results from a randomized, multicentre, open-label, phase 3 trial. Lancet Oncol 17:1061–1069PubMed

31.

Aluwini S, Pos F, Schimmel E et al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomized, non-inferiority, phase 3 trial. Lancet Oncol 17:464–474PubMed

32.

Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D’Souza DP, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Koontz BF, Paulus R, Sandler HM (2016) Randomized phase IIInoninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 34:2325–2332PubMedPubMedCentral

33.

Dearnaley D, Syndikus I, Mossop H et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3CHHiP trial. Lancet Oncol 17:1047–1060PubMedPubMedCentral

34.

Wilkins A, Mossop H, Syndikus I et al (2015) Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localized prostate cancer: 2-year patient-reported outcomes of the randomized, non-inferiority, phase 3CHHiP trial. Lancet Oncol 16:1605–1616PubMedPubMedCentral

35.

Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, Bauman GS, Bahary JP, Ahmed S, Cheung P, Tai KH, Wu JS, Parliament MB, Tsakiridis T, Corbett TB, Tang C, Dayes IS, Warde P, Craig TK, Julian JA, Levine MN (2017) Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 35:1884–1890PubMed

36.

Roach M, DeSilvio M, Lawton C et al (2003) Radiation therapy oncology group 9413. Phase III trial comparing whole pelvic versus prostate only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: radiation therapy oncology group 9413. J Clin Oncol 21:1904–1911PubMed

37.

Lawton CA, DeSilvio M, Roach M et al (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69:646–655PubMedPubMedCentral

38.

Cozzarini C, Fiorino C, Muzio D et al (2007) Significant reduction of acute toxicity following pelvic irradiation with helical Tomotherapy in patients with localized prostate cancer. Radiother Oncol 84:164–170PubMed

39.

Di Muzio N, Fiorino C, Cozzarini C et al (2009) Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 74:392–398PubMed

40.

Di Muzio NG, Fodor A, Noris B et al (2016) Moderate Hypofractionation with simultaneous integrated boost in prostate Cancer: long-term results of a phase I/II study. Clin Oncol 28:490–500

41.

Saracino B, Petrongari MG, Marzi S et al (2014) Intensity-modulatedpelvic radiation therapy and simultaneous integrated boost tothe prostate area in patients with high-risk prostate cancer: apreliminary report of disease control. Cancer Med 3:1313–1321PubMedPubMedCentral

42.

Arcangeli G, Saracino B, Petrongari MG et al (2007) Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area. Radiother Oncol 84:148–155PubMed

43.

Franzese C, Fogliata A, D'Agostino GR et al (2017) Moderate hypofractionated radiotherapy with volumetric modulated arc therapy and simultaneous integrated boost for pelvic irradiation in prostate cancer. J Cancer Res Clin Oncol 143:1301–1309PubMed

44.

McCammon R, Rusthoven KE, Kavanagh B et al (2009) Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer. Int J Radiat Oncol Biol Phys 75:413–420PubMed

46.

Engels B, Soete G, Tournel K et al (2009) Helical tomotherapy with simultaneous integrated boost for high risk and lymph node positiveprostate cancer: early report on acute and late toxicity. Technol Cancer Res Treat 8:353–9

48.

Adkison JB, McHaffie DR, Bentzen SM et al (2012) Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 82:184–190PubMed

49.

Alongi F, Fogliata A, Navarria P et al (2012) Moderate hypofractionation and simultaneous integrated boost with volumetric modulated arc therapy (RapidArc) for prostate cancer. Report of feasibility and acute toxicity. Strahlenther Onkol 188:990–996PubMed

50.

Chang MG, Mukhopadhyay N, Holdford D, Skinner V, Saraiya S, Moghanaki D, Anscher MS (2018) Phase 1/2 study of hypofractionated intensity-modulated radiation therapy for prostate cancer including simultaneously integrated boost. Pract Radiat Oncol 8:e149–e157PubMed

51.

Magli A, Moretti E, Tullio A, Giannarini G, Tonetto F, Urpis M, Crespi M, Foti C, Prisco A, Polsinelli M, de Giorgi G, Bravo G, Scalchi P, Trovò M (2018) Hypofractionated simultaneous integrated boost (IMRT-SIB) with pelvic nodal irradiation and concurrent androgen deprivation therapy for high-risk prostate cancer: results of a prospective phase II trial. Prostate Cancer Prostatic Dis 21:269–276PubMed

Title: Acute and Late Toxicity after Moderate Hypofractionation with Simultaneous Integrated Boost (SIB) Radiation Therapy for Prostate Cancer. A Single Institution, Prospective Study
Authors: Kliton Jorgo
Csaba Polgar
Tibor Major
Gabor Stelczer
Andras Herein
Tamas Pocza
Laszlo Gesztesi
Peter Agoston
Publication date: 01-04-2020
Publisher: Springer Netherlands
Keywords: Prostate Cancer
Prostate Cancer
Radiotherapy
Published in: Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-019-00623-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Asbtract

Please log in to get access to this content

Other articles of this Issue 2/2020

Prognostic Significance of Serum PSA Level and Telomerase, VEGF and GLUT-1 Protein Expression for the Biochemical Recurrence in Prostate Cancer Patients after Radical Prostatectomy

Absence of EGFR C797S Mutation in Tyrosine Kinase Inhibitor-Naïve Non–Small Cell Lung Cancer Tissues

Lactate Dehydrogenase-to-Lymphocyte Ratio Represents a Powerful Prognostic Tool of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors

Dynamic FDG-PET/CT in the Initial Staging of Primary Breast Cancer: Clinicopathological Correlations

Relative and Absolute Expression Analysis of MicroRNAs Associated with Luminal A Breast Cancer– A Comparison

The Role of O6-methylguanine-DNA Methyltransferase Polymorphisms in Prostate Cancer Susceptibility: a Meta-Analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer